DAX ®13.214,19+0,05%TecDAX ®3.018,58-0,01%Dow Jones27.951,00-0,30%NASDAQ 1008.328,06-0,01%
finanztreff.de

BUSINESS WIRE: Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)

| Quelle: Business_Wire | Lesedauer etwa 6 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

LONDON (BUSINESS WIRE) 21.10.2019

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with KALYDECO® (ivacaftor) for eligible patients in Spain living with cystic fibrosis (CF).

Under the terms announced today, children ages 6 to 11 years with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can be treated with ORKAMBI. Patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and a copy of one of the other 14 mutations approved within the license in which the CFTR protein shows residual activity, can be treated with SYMKEVI in combination with KALYDECO.

Ludovic Fenaux, Senior Vice President, Vertex International, commented, “Today’s announcement means ORKAMBI and SYMKEVI can be prescribed from the first of November 2019 for the approximately 600 eligible cystic fibrosis patients living in Spain, to treat the underlying cause of their disease. We thank the Spanish Authorities for their collaboration and commitment to working with us in an innovative way to come to a solution for patients. We would also like to acknowledge the medical community for their important input during this process.”

Vertex’s CF medicines are reimbursed in 17 countries around the world including Austria, Australia, Denmark, Germany, the Republic of Ireland, Italy, the Netherlands, Sweden and the U.S.

About CF
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

About ORKAMBI® (lumacaftor/ivacaftor) and the F508del mutation
In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About SYMKEVI® (tezacaftor/ivacaftor) in combination with KALYDECO® (ivacaftor)
Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney disease.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including nine consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second, third and fifth paragraphs of the press release. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

International Media: +44 20 3204 5275
MediaInfo@vrtx.com

U.S. Media: 617-341-6992
MediaInfo@vrtx.com

Investors: 617-961-7163
InvestorInfo@vrtx.com

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
17:21 BUSINESS WIRE: CutPRO® Cut Resistant Clothing sponsorizza l'importante evento nel settore del vetro ‘Glass Focus 2019’
17:19 BUSINESS WIRE: CutPRO®, Anbieter von Schnittschutzkleidung, Sponsor der Glas-Leitmesse „Glass Focus 2019“
16:59 BUSINESS WIRE: Il mercato mondiale degli hearable totalmente wireless raggiunge i 33 milioni di unità nel terzo trimestre del 2019
16:54 BUSINESS WIRE: Britischer Taschenhersteller Bucklesbury profitiert vom globalen Trend zu mehr Diversität in der Unternehmensführung
16:50 BUSINESS WIRE: XPRIZE annuncia un nuovo concorso con in palio 10 milioni di dollari per la conservazione delle foreste pluviali in tutto il mondo
16:46 BUSINESS WIRE: Il produttore britannico di borse Bucklesbury trae vantaggio dal trend globale verso una leadership commerciale più diversificata
16:38 BUSINESS WIRE: FLIR lancia la linea per carichi StormCaster per i suoi mezzi aerei a pilotaggio remoto SkyRaider e SkyRanger
15:55 BUSINESS WIRE: Globaler Markt für True-Wireless-Kopfhörer erreicht im dritten Quartal 2019 33 Millionen Einheiten
15:45 BUSINESS WIRE: ADVA und PSNC zeigen 1200G Datenkanal auf der SC19 ADVA OPT.NETW.SE O.N. 7,77 +3,60%
15:20 BUSINESS WIRE: SLM Solutions Group AG und Divergent Technologies unterzeichnen Absichtserklärung zum Kauf von AM-Maschinen der nächsten Generation und zur weiteren Vertiefung ihrer strategischen Partnerschaft
Rubrik: Finanzmarkt
17:23 Ölpreise deutlich gefallen
17:20 INDEX-FLASH: Dax und EuroStoxx tauchen mit der Wall Street ins Minus ab DAX ® 13.214,64 +0,06%
17:19 DGAP-Stimmrechte: aap Implantate AG (deutsch) AAP IMPLANTATE AG 0,401 -4,296%
17:19 BUSINESS WIRE: CutPRO®, Anbieter von Schnittschutzkleidung, Sponsor der Glas-Leitmesse „Glass Focus 2019“
17:13 ROUNDUP: 'Besser geht's nicht'? - BGH nimmt Yelp-Bewertungen unter die Lupe
17:12 Kalifornien macht im Grenzwertstreit Druck auf Autohersteller BMW ST 73,35 +0,37%
17:10 AKTIE IM FOKUS 2: Aurbis-Schwung lässt nach - Metallo-Übernahme wird geprüft AURUBIS 48,88 +5,07%
17:09 SPD-Abgeordnete fordern Ausschluss von Huawei bei 5G-Ausbau
17:07 Recht auf Selbsttötung für Schwerkranke? Karlsruhe soll entscheiden
17:05 EU-Wettbewerbshüter nehmen Metallo-Aurubis-Übernahme ins Visier AURUBIS 48,88 +5,07%

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Elon Musk hat vor in der Nähe von Berlin eine Gigafabrik zu bauen. Ist das eher ein Segen für die Region und Deutschland oder eher eine Kampfansage an die deutschen Autobauer?
Jetzt abstimmen!
Alle Umfragen ansehen